slides · global inventory
Traction
Slide type collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 10,471
Current window 5,671-5,700
Pages 350
Rows per page 30
Slide type
5,671-5,700 of 10,471
10
Includes a valuation table and key performance indicators.Grove | Investor Presentation Deck | 41 slides · Grove Collaborative
Pitch deck Investor relations Beat · Rising Success1 hit
17
HPC likely stands for Home and Personal Care.Grove | Investor Presentation Deck | 41 slides · Grove Collaborative
Pitch deck Investor relations Beat · Rising Success1 hit
20
The chart illustrates cohort decay and stabilization over time.Grove | Investor Presentation Deck | 41 slides · Grove Collaborative
Pitch deck Investor relations Beat · Ultimate Achievement1 hit
21
The slide uses a visual of a TV screen displaying a Grove Co. product to reinforce the brand strength message.Grove | Investor Presentation Deck | 41 slides · Grove Collaborative
Pitch deck Investor relations Beat · Ultimate Achievement1 hit
22
The slide uses stacked bar charts to illustrate the shift in revenue mix and the components of gross margin expansion.Grove | Investor Presentation Deck | 41 slides · Grove Collaborative
Pitch deck Investor relations Beat · Ultimate Achievement1 hit
24
The slide uses a dual-chart approach (bar for absolute values, line for YoY growth) to demonstrate efficiency gains.Grove | Investor Presentation Deck | 41 slides · Grove Collaborative
Pitch deck Investor relations Beat · Ultimate Achievement1 hit
27
Slide 27 of the deck.Grove | Investor Presentation Deck | 41 slides · Grove Collaborative
Pitch deck Investor relations Beat · Ultimate AchievementLoop · Quick Win Big Bet1 hit
34
The slide highlights a 'pandemic bump' and a significant reduction in burn rate.Grove | Investor Presentation Deck | 41 slides · Grove Collaborative
Pitch deck Investor relations Beat · Ultimate Achievement1 hit
35
The slide highlights positive trends in both revenue per order and gross margin, with a specific callout for a record high in Q2 2023.Grove | Investor Presentation Deck | 41 slides · Grove Collaborative
Pitch deck Investor relations 1 hit
06
The slide includes a background map watermark and a disclaimer regarding non-GAAP measures.Houlihan Lokey | Investor Presentation Deck | 33 slides · Houlihan Lokey
Pitch deck Investor relations 1 hit
11
The slide uses donut charts to visualize the mix across four categories. It emphasizes low concentration risk with specific 2% thresholds.Houlihan Lokey | Investor Presentation Deck | 33 slides · Houlihan Lokey
Pitch deck Investor relations 1 hit
14
The slide uses two bar charts to demonstrate historical growth and productivity metrics.Houlihan Lokey | Investor Presentation Deck | 33 slides · Houlihan Lokey
Pitch deck Investor relations 1 hit
19
The slide uses a cascading table design to show #1 rankings across multiple sectors.Houlihan Lokey | Investor Presentation Deck | 33 slides · Houlihan Lokey
Pitch deck Investor relations Beat · Business Model1 hit
24
The slide uses a split-layout to combine qualitative value propositions with quantitative market leadership data.Houlihan Lokey | Investor Presentation Deck | 33 slides · Houlihan Lokey
Pitch deck Investor relations 1 hit
26
The slide highlights financial resilience and scalability through market cycles.Houlihan Lokey | Investor Presentation Deck | 33 slides · Houlihan Lokey
Pitch deck Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
27
The chart displays revenue in millions, broken down by Corporate Finance, Financial Restructuring, and Financial and Valuation Advisory.Houlihan Lokey | Investor Presentation Deck | 33 slides · Houlihan Lokey
Pitch deck Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
14
Includes a disclaimer about 2023 figures representing guidance midpoints.Hyperfine | Investor Presentation Deck | 16 slides · Hyperfine
Pitch deck Investor relations Beat · Financial ProfileLoop · Quick Win Big Bet1 hit
06
The slide uses a grouped bar chart to compare clinical outcomes across different patient segments (No BCMA, Yes BCMA, Overall).Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
08
Includes detailed source citations in the footer.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
16
The slide compares two disease indications side-by-side with clinical metrics and competitive market context.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
18
The chart demonstrates deepening clinical responses over time, a key indicator of therapeutic efficacy in oncology trials.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
26
Layout splits into three quadrants of charts (survival %, tumor response %, median survival days) plus a navy summary band; Immix Biopharma logo top-right and page number 26 bottom-right.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
27
Includes a process diagram showing the mechanism of action of IMX-110 in tumor microenvironments.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
28
Includes survival curves (Kaplan-Meier), median survival bar chart, and bioluminescence imaging of tumor growth.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
30
Includes waterfall and spider/line charts for clinical efficacy. Source note at bottom.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
32
The chart visualizes a single data point (4 months mPFS at 100% of patients with >=3 prior lines of therapy) as a highlighted marker.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
38
Includes two sets of charts: tumor volume over time and survival curves for MDA-MB-231 and HCT-116 models.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
12
Includes detailed clinical trial citations in the footer.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
23
The slide uses a two-column layout to contrast clinical results for Multiple Myeloma vs. AL Amyloidosis, supported by market data for existing therapies.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
24
The chart demonstrates deepening clinical responses over time, with sCR/CR increasing from 50% to 83%.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit